AstraZeneca said a late-stage trial confirmed the benefit of breast cancer drug Enhertu in patients with an innovative form of the disease who formerly treated with another therapy. AstraZeneca protected partial rights to the Daiichi Sankyo compound three years ago in a deal worth up to $6.9 billion.